Zhu et al. [25] reported a significant reduction in the need of revascularization in ACS patients treated with SGLT2 inhibitors, notably, only this study included both patients with and without diabetes, while the others were restricted to individuals with type 2 diabetes, Figure 8E. This could partially explain the stronger protective effect observed in Zhu’s cohort, potentially pointing to broader vascular benefits of SGLT2i beyond glycemic control, after its exclusion, the heterogeneity I2 = 43.5%. This evidence concerns the gene SLC5A2 and diabetes mellitus.